Abstract
Objectives: Evaluate impact of 24 hour CT head on post-alteplase management decisions. Background: According to American Heart Association guidelines, patients with ischemic strokes who receive alteplase should have a 24 hour CT head to evaluate for hemorrhagic conversion. Effects of CT on patient management and detecting hemorrhages without neurological deterioration is unclear. Methods: Patients given alteplase and cared for at University of North Carolina Hospitals between January 1, 2012 and June 30, 2015 were extracted from Get with the Guidelines database. Patient records were reviewed for presence of hemorrhagic conversion, symptomatic hemorrhage (NIHSS change), and management changes. Cases with hemorrhagic conversion were collected and divided into symptomatic vs asymptomatic. Percentages of documented management changes related to hemorrhagic conversion were calculated. Results: 280 patients included, 25(8.9[percnt]) had hemorrhagic transformation (10 symptomatic, 14 asymptomatic and 1 unknown had hemorrhage at another hospital). Those with hemorrhage had an older average age (73 vs 65) and higher NIHSS (18 vs 11). Of 14 patients with asymptomatic hemorrhage, antithrombotics were held in 9(64[percnt]) for 1-7 days. Four asymptomatic patients had no delay in antithrombotics without complication and one made comfort care. Conclusion: For 95[percnt] of asymptomatic patients, a 24 hour post-alteplase CT head had no clinical impact. Antithrombotic treatment was delayed by asymptomatic hemorrhage in 2/3 of patients, depriving them of early antiplatelet therapy that reduces the risk of stroke within the first 14 days (Lancet. 349:1569-81). With an estimated 30,000 doses of alteplase given in US, cost of routine CT screening is significant at $6.6 million per year (Jt Comm J Qual Patient Saf. 41:313-22), and there is increased risk of cancer from radiation of 1/10000 (Arch Intern Med. 169:2078-86). Further studies are needed to determine if benefit of withholding antithrombotics for asymptomatic hemorrhagic transformation exists and whether benefit outweighs cost of widespread screening.
Disclosure: Dr. Sevilis has nothing to disclose. Dr. Morantes Gomez has nothing to disclose. Dr. Shah has nothing to disclose. Dr. Wang has nothing to disclose. Dr. Huang has received personal compensation for activities with Aldagen/Cytomedix and Dart Neuroscience as a consultant. Dr. Powers has nothing to disclose.
Thursday, April 21 2016, 1:00 pm-3:00 pm
- Copyright © 2016 by AAN Enterprises, Inc.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
